Autonomic and Immune Effects of Regional Anesthesia in Total Hip Arthroplasty (PENG neuromodu)
Effects of Three Regional Anesthesia Strategies on Autonomic Regulation, Systemic Inflammatory Response, and Postoperative Recovery Following Elective Total Hip Arthroplasty: A Prospective Randomized Double-Blind Trial
Surgical trauma activates the sympathetic nervous system and induces a systemic inflammatory response, both of which may adversely affect postoperative recovery. Regional anesthesia has traditionally been used for perioperative analgesia; however, emerging evidence suggests that peripheral nerve blocks may also modulate autonomic and immune pathways. This prospective randomized double-blind trial aims to compare three regional anesthesia strategies in patients undergoing elective total hip arthroplasty under spinal anesthesia and to determine their effects on autonomic regulation, systemic inflammatory response, postoperative pain, opioid consumption, quality of recovery, and early functional outcomes.
調査の概要
詳細な説明
Total hip arthroplasty (THA) is associated with substantial surgical trauma, resulting in activation of the sympathetic nervous system and a systemic inflammatory response that may contribute to postoperative pain, delayed functional recovery, and perioperative complications. Although regional anesthesia techniques are widely used to improve postoperative analgesia, increasing evidence suggests that they may also influence autonomic regulation and neuroimmune interactions beyond their analgesic effects. The extent to which different regional anesthesia strategies modify perioperative autonomic and inflammatory responses remains incompletely understood.
This prospective, randomized, double-blind, controlled trial aims to compare three regional analgesic strategies in patients undergoing elective primary total hip arthroplasty under spinal anesthesia: ultrasound-guided pericapsular nerve group (PENG) block, local infiltration analgesia (LIA), and the combination of PENG block with LIA. All patients will receive standardized perioperative anesthetic and multimodal analgesic management, with the regional analgesic technique being the only study intervention.
The primary objective is to determine whether different regional anesthesia strategies differentially influence perioperative autonomic regulation and systemic inflammatory response. Autonomic function will be assessed using perioperative hemodynamic parameters and vasopressor requirements, while systemic inflammatory activation will be evaluated using routinely available inflammatory biomarkers, including the Systemic Immune-Inflammation Index (SII), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), C-reactive protein (CRP), and other laboratory markers measured before and after surgery.
Secondary objectives include comparison of postoperative pain intensity at rest and during movement, opioid consumption, time to first rescue analgesia, quality of recovery assessed using the Quality of Recovery-15 (QoR-15) questionnaire, incidence of postoperative nausea and vomiting, time to first ambulation, length of hospital stay, patient satisfaction, and the incidence of postoperative complications.
The study is designed to determine whether combining peripheral nerve blockade with periarticular infiltration provides additive benefits not only for postoperative analgesia but also for modulation of autonomic-immune interactions and enhancement of postoperative recovery. The findings may improve understanding of peripheral nerve blocks as a form of perioperative neuromodulation and support optimization of regional anesthesia strategies in patients undergoing total hip arthroplasty.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前：Malgorzata Reysner, MD PhD
- 電話番号：+48 61 8310122
- メール：mreysner@ump.edu.pl
研究場所
-
-
-
Poznan、ポーランド、62-701
- Poznan University of Medical Sciences
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Adults aged ≥18 years.
- Scheduled for elective primary total hip arthroplasty due to primary hip osteoarthritis.
- American Society of Anesthesiologists (ASA) physical status I-III.
- Planned spinal anesthesia with one of the study regional analgesia techniques.
- Ability to understand the study procedures and provide written informed consent.
Exclusion Criteria:
- Refusal or inability to provide written informed consent.
- Revision hip arthroplasty, simultaneous bilateral hip arthroplasty, or hip arthroplasty performed for an acute fracture.
- Known hypersensitivity to ropivacaine or other medications required for the study procedures.
- Contraindication to spinal anesthesia, PENG block, or local infiltration analgesia, including infection at the injection site or a coagulation disorder or antithrombotic treatment that precludes safe performance of the planned procedures.
- Pre-existing neurological or neuromuscular disease that substantially affects sensation or motor function in the operated limb or prevents reliable assessment of study outcomes.
- Cognitive impairment or a communication disorder that prevents understanding of the study procedures or reliable completion of pain assessments.
- A medical condition that, in the investigator's judgment, makes participation or the planned anesthetic procedures unsafe.
- Planned use of an additional regional analgesic technique outside the study protocol.
- Participation in another interventional study that could interfere with the assessment of the study outcomes.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：PENG Block
Ropivacaine for Pericapsular Nerve Group (PENG) Block |
Ultrasound-guided single-injection pericapsular nerve group (PENG) block performed before surgery using 20ml of 0.2% ropivacaine
他の名前：
|
|
実験的：Local Infiltration Analgesia (LIA)
Ropivacaine for Local Infiltration Analgesia |
Local infiltration analgesia is performed intraoperatively - 20ml 0.2% ropivacaine
他の名前：
|
|
実験的：Combined PENG Block + LIA
Ropivacaine for Pericapsular Nerve Group (PENG) block before surgery and Local Infiltration Analgesia (LIA) |
Ultrasound-guided single-injection pericapsular nerve group (PENG) block performed before surgery using 20ml of 0.2% ropivacaine
他の名前：
Local infiltration analgesia is performed intraoperatively - 20ml 0.2% ropivacaine
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Systemic Immune-Inflammation Index (SII)
時間枠：24 hours after surgery
|
Comparison of the change in Systemic Immune-Inflammation Index from baseline to postoperative 24 hours among the three study groups. |
24 hours after surgery
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Neutrophil-to-Lymphocyte Ratio (NLR)
時間枠：24 hours after surgery
|
Comparison of the change in neutrophil-to-lymphocyte ratio among the three study groups. |
24 hours after surgery
|
|
Neutrophil-to-Lymphocyte Ratio (NLR)
時間枠：12 hours after surgery
|
Comparison of the change in neutrophil-to-lymphocyte ratio among the three study groups. |
12 hours after surgery
|
|
Neutrophil-to-Lymphocyte Ratio (NLR)
時間枠：48 hours after surgery
|
Comparison of the change in neutrophil-to-lymphocyte ratio among the three study groups. |
48 hours after surgery
|
|
Platelet-to-Lymphocyte Ratio (PLR)
時間枠：24 hours after surgery
|
Comparison of the change in platelet-to-lymphocyte ratio among the three study groups. |
24 hours after surgery
|
|
Platelet-to-Lymphocyte Ratio (PLR)
時間枠：48 hours after surgery
|
Comparison of the change in platelet-to-lymphocyte ratio among the three study groups. |
48 hours after surgery
|
|
Platelet-to-Lymphocyte Ratio (PLR)
時間枠：12 hours after surgery
|
Comparison of the change in platelet-to-lymphocyte ratio among the three study groups. |
12 hours after surgery
|
|
Postoperative pain intensity
時間枠：2 hours after surgery
|
Comparison of postoperative pain intensity assessed using the Numeric Rating Scale (NRS; 0-10) at rest. |
2 hours after surgery
|
|
Postoperative pain intensity at movement
時間枠：2 hours after surgery
|
Comparison of postoperative pain intensity assessed using the Numeric Rating Scale (NRS; 0-10) at movement. |
2 hours after surgery
|
|
Postoperative pain intensity at movement
時間枠：6 hours after surgery
|
Comparison of postoperative pain intensity assessed using the Numeric Rating Scale (NRS; 0-10) at movement. |
6 hours after surgery
|
|
Postoperative pain intensity at movement
時間枠：12 hours after surgery
|
Comparison of postoperative pain intensity assessed using the Numeric Rating Scale (NRS; 0-10) at movement. |
12 hours after surgery
|
|
Postoperative pain intensity at movement
時間枠：24 hours after surgery
|
Comparison of postoperative pain intensity assessed using the Numeric Rating Scale (NRS; 0-10) at movement. |
24 hours after surgery
|
|
Postoperative pain intensity at movement
時間枠：48 hours after surgery
|
Comparison of postoperative pain intensity assessed using the Numeric Rating Scale (NRS; 0-10) at movement. |
48 hours after surgery
|
|
Postoperative pain intensity
時間枠：6 hours after surgery
|
Comparison of postoperative pain intensity assessed using the Numeric Rating Scale (NRS; 0-10) at rest. |
6 hours after surgery
|
|
Postoperative pain intensity
時間枠：12 hours after surgery
|
Comparison of postoperative pain intensity assessed using the Numeric Rating Scale (NRS; 0-10) at rest. |
12 hours after surgery
|
|
Postoperative pain intensity
時間枠：24 hours after surgery
|
Comparison of postoperative pain intensity assessed using the Numeric Rating Scale (NRS; 0-10) at rest. |
24 hours after surgery
|
|
Postoperative pain intensity
時間枠：48 hours after surgery
|
Comparison of postoperative pain intensity assessed using the Numeric Rating Scale (NRS; 0-10) at rest. |
48 hours after surgery
|
|
Postoperative opioid consumption
時間枠：48 hours after surgery
|
Comparison of cumulative opioid consumption during the postoperative period, expressed as intravenous morphine milligram equivalents (MME). |
48 hours after surgery
|
|
Time to first rescue analgesia
時間枠：48 hours after surgery
|
Comparison of the time from the end of surgery to the first administration of rescue opioid analgesia. |
48 hours after surgery
|
|
Systemic Immune-Inflammation Index (SII)
時間枠：24 hours after surgery
|
Comparison of the change in the Systemic Immune-Inflammation Index (SII) among the three study groups. |
24 hours after surgery
|
|
Systemic Immune-Inflammation Index (SII)
時間枠：12 hours after surgery
|
Comparison of the change in the Systemic Immune-Inflammation Index (SII) among the three study groups. |
12 hours after surgery
|
|
Systemic Immune-Inflammation Index (SII)
時間枠：48 hours after surgery
|
Comparison of the change in the Systemic Immune-Inflammation Index (SII) among the three study groups. |
48 hours after surgery
|
|
C-reactive protein (CRP)
時間枠：12 hours after surgery
|
Comparison of postoperative C-reactive protein (CRP) concentrations among the three study groups. |
12 hours after surgery
|
|
C-reactive protein (CRP)
時間枠：24 hours after surgery
|
Comparison of postoperative C-reactive protein (CRP) concentrations among the three study groups. |
24 hours after surgery
|
|
C-reactive protein (CRP)
時間枠：48 hours after surgery
|
Comparison of postoperative C-reactive protein (CRP) concentrations among the three study groups. |
48 hours after surgery
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 18/2026
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
De-identified individual participant data underlying the published results will be made available upon reasonable request to the corresponding author. Data will be shared after publication of the primary study results and following approval of a methodologically sound research proposal and completion of a data sharing agreement.
IPD 共有時間枠
Data will be available beginning 6 months after publication of the primary results and for a period of 5 years.
IPD 共有アクセス基準
Researchers who provide a methodologically sound proposal aimed at achieving the objectives of the approved proposal will be granted access. Requests should be directed to the corresponding author. A data access agreement will be required prior to data release.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ANALYTIC_CODE
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。